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Abstract: Breast cancer is the most frequent tumor among women worldwide and is the second 
cause of cancer-related mortality in the US. Metastatic breast cancer (MBC) accounts for less 
than 10% of newly diagnosed breast cancer patients and about 30% of early breast cancer 
patients will develop recurrent, advanced, or metastatic disease. It remains an incurable illness 
and the primary goal of its management is palliative. Several agents are active for the ﬁ  rst-line 
treatment of MBC. The taxanes, paclitaxel and docetaxel, represent the standard of care for 
the treatment of these patients. Among the various schedules, docetaxel can be administered 
weekly, achieving similar efﬁ  cacy results with lower toxicity compared with conventional 
schedules. Weekly docetaxel (25–40 mg/m2) has been widely tested in several phase I and II 
studies both as a single agent and in multichemotherapy regimens, reaching overall response 
rates ranging from 26% and 86% or 20% and 73% with docetaxel alone or in combination, 
respectively, depending on doses, associations, and line of treatment. Overall, published data 
support the administration of weekly docetaxel for the treatment of MBC patients even if data 
from phase III randomized trials are still lacking.
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Introduction
Breast cancer is the most frequent tumor among women worldwide and represents the 
second cause of cancer-related mortality in the US (SEER 2008).
Metastatic breast cancer (MBC) is uncommon as initial presentation, accounting for 
less than 10% of newly diagnosed breast cancer patients (SEER 2008). Despite optimi-
zation of treatment for early breast cancer, about 30% of women will develop recurrent, 
advanced, or metastatic disease. By 2003, 5-year relative survival exceeded 90% and 
80% respectively for localized and regional breast cancer, while it did not reach 30% 
for MBC (Brenner et al 2007; Hayat et al 2007). The majority of breast cancer-related 
deaths are a result of complications from recurrent or metastatic disease.
MBC remains an incurable illness. The primary goal of its management is palliative and 
aims to improve quality of life, prolong disease-free survival (DFS) and possibly overall 
survival (OS). The main treatment modalities include endocrine therapy, cytotoxic chemo-
therapy and biological agents. The best option should be established considering multiple 
prognostic and predictive factors such as hormonal receptor status, HER-2 overexpression, 
growth rate, presence of visceral metastases, history of prior therapy and response.
Chemotherapy clearly provides tumor shrinkage and substantial clinical beneﬁ  t in 
advanced breast cancer (Stockler et al 2000), so that it is accepted as standard treat-
ment for hormone-resistant and rapidly progressive disease. On the other hand, no 
randomized trials comparing chemotherapy with supportive care only are available 
and such kinds of studies are unlikely to be considered ethical in the future.
Several agents are active for the ﬁ  rst-line treatment of MBC, anthracyclines and 
taxanes being the most effective (Table 1).Therapeutics and Clinical Risk Management 2008:4(5) 1048
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Anthracyclines provide an overall response rate (ORR) 
ranging from 35% to 50% as ﬁ  rst-line single agents (Find-
lay et al 1998). Nowadays they are extensively used in the 
adjuvant setting so that many patients with recurrent disease 
may have already had a signiﬁ  cant anthracycline exposure. 
Therefore taxane-based regimens are frequently considered 
for this subset of MBC patients.
Platinum compounds, alkylating agents, antimetabolites, 
and vinca-alkaloids might be also considered alone or in 
combination for the ﬁ  rst-line treatment of MBC patients 
based on their single-agent activity (ORRs ranging from 
18% to 52%) (Colozza et al 2007).
Several novel biological agents have recently started 
to be tested in such a setting of treatment: to date, only 
trastuzumab and bevacizumab, monoclonal antibodies 
against Her2/neu receptor and the vascular endothelial 
growth factor, respectively, have obtained regulatory agency 
approval, both in the US and in Europe. Trastuzumab is the 
standard therapy for HER-2 overexpressing tumors, both 
for early and advanced breast cancer patients, with response 
rates ranging from 50% to 70% with combination treatment 
(Slamon et al 2001; Burstein et al 2003; Marty et al 2005) 
and from 20% to 30% with monotherapy in the metastatic 
setting (Piccart-Gebhart et al 2005; Romond et al 2005). 
Bevacizumab has recently been approved for the ﬁ  rst-line 
treatment of MBC patients, since its addiction to paclitaxel 
led to a signiﬁ  cant prolongation of progression-free survival 
(median, 11.8 versus 5.9 months; hazard ratio [HR] for 
progression, 0.60; p  0.001) and an increase in the objec-
tive response rate (36.9% versus 21.2%, p  0.001) when 
the association was compared with single-agent paclitaxel 
(Miller et al 2007).
The results of the AVADO trial, comparing the efﬁ  cacy 
of the association of bevacizumab (7.5 or 15 mg/kg) and 
docetaxel (100 mg/m2) with the standard 3-week docetaxel 
(100 mg/m2) as ﬁ  rst-line treatment for MBC, were presented 
at the ASCO 2008 Annual Meeting (Miles et al 2008). 
Signiﬁ  cant improvements in both progression-free survival 
(HR 0.79, CI 0.63–0.98, p = 0.0318 for bevacizumab at 
7.5 mg/kg; HR 0.72, CI 0.57–0.90, p = 0.0099 for bevacizumab 
15 mg/kg) and ORR (44.4% versus 55.2%, docetaxel alone 
versus the arm with bevacizumab 7.5 mg/kg, p = 0.0295; 
44.4% versus 63.1%, docetaxel alone versus the arm with 
bevacizumab 15 mg/kg, p = 0.0001) have been found 
for the bevacizumab-containing arms compared with the 
docetaxel-alone arm.
The taxanes
The taxanes, paclitaxel and docetaxel, represent a milestone 
in the treatment of MBC. Although their synthesis began in 
the late 1970s, the clinical development for advanced breast 
cancer treatment burgeoned in the 1990s, when the ﬁ  rst phase 
II trials documented their antitumor activity as single agents 
(Holmes et al 1991; Ringel et al 1991; D’Andrea et al 1997; 
Valero et al 1995).
Since then, data from prospective randomized phase 
III studies conﬁ  rmed their activity and proved their efﬁ  -
cacy, with single-agent paclitaxel and docetaxel providing 
similar OS rates compared with the previous gold standard 
anthracycline, doxorubicin (Chan et al 1999; Paridaens et al 
2000; Sledge et al 2003). Moreover they demonstrated a 
signiﬁ  cant activity in anthracycline-resistant patients and an 
acceptable toxicity proﬁ  le (Ravdin et al 1995; Seidman et al 
1995a, b; Nabholtz et al 1996, 1997).
In 2005, Ghersi et al published a comprehensive 
meta-analysis of all published and unpublished tri-
als comparing regimens containing taxanes with those 
containing non-taxanes in the ﬁ  rst-line and further lines of 
treatment in MBC, and found that taxanes combinations 
improved OS, time to progression (TTP), and ORR (Ghersi 
et al 2005). They also conducted a post-hoc sub-group analy-
sis in order to investigate the treatment effect within the type 
of taxane. Data from the analysis of trials using paclitaxel 
showed no difference between the two arms for OS (HR 0.97; 
95% CI = 0.87–1.07, p = 0.54), but when the taxane used was 
docetaxel there was a statistically signiﬁ  cant difference in 
OS in favor of taxane-containing regimens (HR 0.88; 95% 
CI = 0.78–0.98, p = 0.02).
In previously untreated patients, single-agent docetaxel 
provides ORR of 40% to 68% (Cortes et al 1995; Valero 
1997) while in anthracycline-resistant patients ORR is 
53%–57% (Ravdin et al 1995; Valero et al 1995).
Table 1 Most active drugs in ﬁ  rst-line treatment of metastatic 
breast cancer and range of activity
Objective response rate (%)
Adriamycin1 40–50
Epirubicin1 52–68
Paclitaxel2 29–63
Docetaxel3 47–65
Vinorelbine4 18–52
Gemcitabine4 25–46
Capecitabine5–7 20–30
Carboplatin8 20–35
1Findlay et al 1998; 2Paridaens et al 2000; 3Chan et al 1999; 4Hortobagyi 1998; 5Blum 
et al 1999; 6Blum et al 2001; 7Fumoleau et al 2004; 8Perez 2004.
Abbreviation: ORR, complete + partial response.Therapeutics and Clinical Risk Management 2008:4(5) 1049
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The ﬁ  rst schedules of administration of docetaxel employed 
doses ranging from 75 to 100 mg/m2 as a 1-hour intravenous 
infusion every three weeks. The 3-week schedule of docetaxel 
100  mg/m2, although extremely active, showed an important 
myelosuppression with more than 90% of cases experiencing 
grade (G) 3–4 neutropenia (Ravdin et al 1995; Valero et al 1995), 
with frequent non hematologic side effects including fatigue, alo-
pecia, skin reactions, nails toxicity, ﬂ  uid retention syndrome.
In pre-treated, elderly or poor performance status patients 
the 3-week dose of 100 mg/m2 must be frequently reduced to 
75 mg/m2 (O’Brien et al 1999; Salminen et al 1999).
Furthermore, such a toxicity proﬁ  le made it difﬁ  cult to 
combine docetaxel with other active chemotherapeutic agents, 
limited its use in unﬁ  t patients and affected dose-intensity.
In order to go beyond these difﬁ  culties new treatment regi-
mens of docetaxel have been proposed and the weekly adminis-
tration has been widely experimented during the last years.
In fact, the weekly schedule provides a remarkable 
reduction of toxicities, especially hematologic, while main-
taining the high activity of docetaxel. An additional advantage 
for the weekly schedule might be an equivalent dose intensity 
of treatment compared with the three-week administration of 
docetaxel at the dose of 100 mg/m2, so allowing a prolonged 
exposure to the drug of the different tumor cell clones, pre-
venting the emergence of resistant clones.
Docetaxel is also a potent and potentially speciﬁ  c inhibitor 
of endothelial cell migration in vitro and angiogenesis in vitro 
and in vivo. The antiangiogenic activity of docetaxel in vivo 
was assessed by Hotchkiss et al In this assay, the angiogenic 
response to ﬁ  broblast growth factor 2 was inhibited in vivo 
by docetaxel with an ID50 of 5.4 mg/kg when injected twice 
weekly over a 14-day period and angiogenesis was com-
pletely blocked in mice that received 10 mg/kg docetaxel 
(Hotchkiss et al 2002).
Our review focus on the role of the weekly schedule of 
administration of docetaxel as single agent therapy and as a part 
of combination regimens for the treatment of MBC patients.
Weekly single-agent docetaxel: 
phase I studies
Many phase I trials of weekly docetaxel, either as single 
agent or in combination, have been carried out and published 
(Table 2).
Table 2 Selected phase I trials on weekly docetaxel
Author and year of publication N. of pts (BC pts) Regimen MTD – DLT
Weekly single-agent docetaxel
Tomiak et al 1994 31 (6) Doc 20–55 mg/m2 d 1, 8 q 21 55 mg/m2 – neutropenia
Hainsworth et al 1996 38 (7) Doc 20–52 mg/m2 qw × 6w (2 w rest) 43 mg/m2 – fatigue –asthenia
Luck et al 1997 18 (all) Doc 30–50 mg/2 qw MTD not reached – no DLT
Lofﬂ  er et al 1998 31 (all) Doc 30–45 mg/m2 qw × 6w (2 w rest) 40–45 mg/m2 – leukopenia
Briasoulis et al 1999 26 (1) Doc 25–50 mg/m2 qw 50 mg/m2 – leukopenia
Kourossis et al 2000 26 (19) Doc 30–45 mg/m2 qw × 3w (1 w rest) 42 mg/m2 – neutropenia
Nisticò et al 2005 28 (all) Doc 30–40 mg/m2 qw × 24 w 35 mg/m2 – asthenia
Weekly docetaxel in combination with chemotherapeutic agents
Frasci et al 2000 34 (all) Doc 30–45 mg/m2 d 1, 8 q 3w
with Gem 1000 mg/m2 d 1, 8 q 3w
or VNR 25 mg/m2 d 1,8 q 3w
50 mg/m2 – neutropenia
Ito et al 2001 25 Doc 25–30 mg/m2 qw × 6w
with Dox 15–20 mg/m2 qw × 6w 
30 mg/m2 – neutropenia
Wenzel et al 2002 13 (all) Doc 25–40 mg/m2 qw × 6w (1w rest)
with Epidox 25–35 mg/m2 qw × 6w (1w rest)
40 mg/m2 – neutropenia
Brugnatelli 2002 18 (all) Doc 30–40 mg/m2 qw × 3w (1w rest)
with Gem 800 mg/m2 qw × 3w (1w rest)
40 mg/m2 – asthenia – 
stomatitis – leukopenia
Ibrahim et al 2007 11 (all) Doc 20–25 mg/m2 qw × 3w (1w rest)
with Dox 30–40 mg/m2 + Cyc 500 mg/m2 
qw × 3w (1w rest)
20 mg/m2 – febrile neutropenia
Abbreviations: Pts, patients; BC, breast cancer; MTD, maximum tolerated dose; DLT, dose limiting toxicity; w, week; Doc, docetaxel; Gem, gemcitabine; VNR, vinorelbine; 
Epidox, epidoxorubicin; Dox, doxorubicin; Cyc, cyclophosphamide.Therapeutics and Clinical Risk Management 2008:4(5) 1050
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In 1994, Tomiak et al evaluated first the weekly 
administration of docetaxel in 32 patients with advanced 
refractory cancer, at doses ranging from 20 to 110 mg/m2 on 
days 1 and 8 of a 21-day cycle (Tomiak et al 1994).
The first phase I study, investigating a 6-week 
consecutive administration of docetaxel with a 2-week 
rest period, was initiated in 1996 by Hainsworth et al 
to define the optimum dose of weekly docetaxel. 
Thirty-eight patients (7 with refractory breast cancer), 
included in sequential cohorts, received escalating 
doses of docetaxel (20–52 mg/m2/week) until dose-
limiting toxicity (DLT) occurred. They reported fatigue 
and asthenia as the DLTs for this regimen. No patient 
showed G4 leucopenia at any dose level. In this study 
the maximum tolerated dose (MTD) was 43 mg/m2/
week (corresponding to a dose-intensity of 126 mg/m2 
every 3 weeks) (Hainsworth et al 1998).
In 1997, Luck et al performed a phase I trial on 18 pre-
treated advanced breast cancer patients. Dose levels between 
30 and 50 mg/m2 were used weekly: no DLT occurred and 
the MTD was not reached (Luck et al 1997).
Loefﬂ  er et al conducted a phase I/II trial on 31 patients with 
advanced breast cancer. Weekly docetaxel (30–45 mg/m2/week) 
was administered for 6 consecutive weeks followed by a 
2-week rest period. An ORR of 50% was reported. The 
recommended dose for phase II trials was 40 mg/m2/
week (Loefﬂ  er et al 1998).
In another subsequent phase I study, Briasoulis et al 
treated 36 cancer patients with weekly docetaxel at 
doses ranging from 25 to 50 mg/m2/week. They found 
myelosuppression and diarrhea being the DLTs and 
suggested the dose of 40 mg/m2/week for further investiga-
tions (Briasoulis et al 1999).
In the study conducted by Kourossis et al in 26 advanced 
solid tumors patients (19 with MBC), the authors reported an 
ORR of 39% and recommended a dose of 40 mg/m2/week 
(Kouroussis et al 2000).
Nisticò et al conducted a phase I/II trial on 28 patients with 
pretreated MBC. Weekly docetaxel was administered weekly 
at a dose range of 30–40 mg/m2/week for 24 consecutive 
weeks (Nistico et al 2005). The suggested dose for phase II 
trials was 35 mg/m2/week. Two out of 28 evaluable patients 
(7.1%) showed complete response (CR), 8 partial response 
(PR) (28.6%), and 8 stable disease (SD) (28.6%). Median 
TTP and OS were 5 and 15 months, respectively. Only one 
G3 neutropenia occurred, while severe asthenia was the 
main reason for treatment stop (10 patients, 35.5%) before 
the planned 24 weeks.
Overall, these tested weekly dosages are equivalent to a 
dose range of 105–120 mg/m2 every 3 weeks.
Weekly docetaxel in combination 
regimens: phase I studies
The favorable results arising from single-agent use prompted 
its combination with other active drugs (Table 2).
In 2000, Frasci et al studied the association between 
escalating doses of docetaxel (starting from 30 mg/m2) and 
either gemcitabine 1000 mg/m2 or vinorelbine 25 mg/m2, 
all on days 1 and 8 every three weeks for the treatment 
of 34 anthracyclines pre-treated MBC patients; 24 out of 
34 had received weekly dose-dense paclitaxel as second-line 
treatment (Frasci et al 2000). Docetaxel at the dose of 40 and 
35 mg/m2 proved to be safe when combined with gemcitabine 
and vinorelbine respectively. An ORR of 15% was observed 
(95% CI: 5%–31%) and only 1 of 24 paclitaxel pretreated 
patients responded to treatment.
Twenty-ﬁ  ve patients with advanced breast cancer were 
treated by Ito et al with an intravenous bolus of doxorubicin 
(15–20 mg/m2), immediately followed by a 1-h infusion of 
docetaxel (25–30 mg/m2), every week for 6 weeks (Ito et al 
2001). MTD was 20 mg/m2 and 30 mg/m2 for doxorubicin 
and docetaxel, respectively. Overall, modest neutropenia 
was reported with no febrile episodes with doxorubicin 
15 or 20 mg/m2 and docetaxel 25 mg/m2 or lower. Reported 
G3 non-hematologic toxicities included asthenia in 4% of 
patients, anorexia in 8%, and vomiting in 8%. The ORR was 
56% (14/25 with partial response). The recommended dose 
for further investigation was 20 mg/m2 of doxorubicin and 
25 mg/m2 of docetaxel.
Weekly epidoxorubicin (25–35 mg/m2) and docetaxel 
(25–40 mg/m2) given once a week for 6 weeks followed by 
1-week rest were evaluated for the preoperative and pallia-
tive treatment of patients with breast cancer by Wenzel et al 
DLT was neutropenic fever, occurring with 35 mg/m2 of 
epidoxorubicin and 40 mg/m2 of docetaxel. Epidoxorubicin 
30 mg/m2 and docetaxel 35 mg/m2 were suggested for further 
evaluations (Wenzel et al 2002).
In order to determine the maximum tolerable dose of 
docetaxel in association with gemcitabine, both given on a 
weekly schedule, Brugnatelli et al designed a phase I study using 
three escalating doses of docetaxel (30, 35, and 40 mg/ m2) 
followed by a ﬁ  xed dose of gemcitabine, 800 mg/m2, on days 1, 
8, and 15 of a 28-day cycle (Brugnatelli et al 2002). Asthenia, 
stomatitis, and leukopenia were the main DLTs. An objective 
response rate of 58% was found and the dose of 35 mg/m2 was 
proposed for further phase II evaluation.Therapeutics and Clinical Risk Management 2008:4(5) 1051
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In a recent phase I trial, 11 MBC patients were enrolled 
in an open, single-arm phase I escalation trial in 3–6 patients/
cohort (Ibrahim et al 2007). The treatment schedule was: 
docetaxel 20 mg/m2 (or 25, depending on dose level assign-
ment) on day 1, 8, 15 in association with doxorubicin 40 or 
50 mg/m2 and cyclophosphamide 500 mg/m2 on day 1, every 
4 weeks. Five patients were allocated to dose level 20/50 
(docetaxel/doxorubicin) and 6 to dose level 20/40. MTD 
was deﬁ  ned at 20 mg/m2 for docetaxel in combination with 
doxorubicin 40 mg/m2 and cyclophosphamide 500 mg/m2, 
due to DLT febrile neutropenia.
Weekly single-agent docetaxel: 
phase II studies
Several phase II trials have evaluated the weekly administra-
tion of single-agent docetaxel in MBC patients (Table 3).
In 2000 Burstein et al published the results of a study of 
weekly docetaxel administered at the dose of 40 mg/m2/week 
to 29 patients (Burstein et al 2000). The authors reported an 
ORR of 41% (all PRs), with similar results for both ﬁ  rst- 
and second-line treatment (21% of second-line patients). 
Grade 3 toxicities, most commonly neutropenia and fatigue, 
were reported in 28% of patients, whereas fatigue, ﬂ  uid 
retention, and eye tearing/conjunctivitis were found to be 
related to cumulative dose. Dose reductions were required 
for 8 patients, mostly due to fatigue.
Jackisch et al (2000) presented, in abstract form, the 
preliminary results of a multicentric phase II study designed 
to determine response rate and toxicity of weekly docetaxel 
35–40 mg/m2 in 60 MBC patients (second line 1.9%, third 
line 98.1%). Overall 24 patients (42.9%) were pretreated 
with anthracyclines for MBC. The reported ORR was 
33.4% including 4/60 CR (6.7%) and 16/60 PR (26.7%). 
Regarding toxicity, 23/652 (3.5%) cycles were associated 
with G3 neutropenia, and 2/652 (0.3%) cycles with G3/4 
thrombocytopenia. Non-hematologic G3 side effects were: 
14.3% alopecia, 1.2% skin disorder, 0.8% neurotoxicity, 
0.8% mucositis, 0.8% nausea/vomiting, 1% ﬂ  uid retention, 
with no G4 non-hematologic toxicities. The authors found 
this schedule safe and feasible, achieving good response rates 
in heavily pretreated MBC patients.
Stemmler et al (2001) conducted a phase II trial in 35 
previously treated MBC patients. Docetaxel 35 mg/m2/week 
for 6 weeks followed by 2 weeks of rest was administered 
with an ORR of 34%. A median survival of 11 months and 
a progression-free survival of 2.6 months were reported. G3 
neutropenia was observed in 3 patients.
Hainsworth et al (2001) tested a weekly schedule of 
docetaxel 36 mg/m2/week in 41 elderly (median age 74 years) 
or poor performance status MBC patients (75% as ﬁ  rst-line 
treatment). In this cohort 36% had an ORR, median TTP was 
7 months, and median survival was 13 months. Fatigue was 
the most common G3/4 non-hematologic toxicity.
In another phase II study, 37 MBC patients (previously 
treated in 92% of cases) received docetaxel at 40 mg/m2/week 
for 3 consecutive weeks with 1-week rest (Aihara et al 2002). 
Table 3 Recent selected phase II trials on weekly docetaxel
Author and year of publication N. of pts (line) Regimen ORR
Weekly single-agent docetaxel
Burstein et al 2000 29 (21% 2nd line) 40 mg/m2 qw 41%
Jackisch et al 2000 60 (93.3% 2nd or  line) 35–40 mg/m2 qw 33.4%
Stemmler et al 2001 35 (all 2nd or  line) 35 mg/m2 qw × 6w (2 w rest) 34%
Aihara et al 2002 37 (all 2nd or  line) 40 mg/m2 qw × 3w (1 w rest) 38% (32 evaluable pts)
Hainsworth et al 2001 41 (25% 2nd or  line) 36 mg/m2 qw 36%
Ramos et al 2003 35 (all Anthra resistant) 36–40 mg/m2 qw × 6w (2 w rest) 34%
D’Hondt et al 2004 47 (79% 2nd or  line) 36 mg/m2 qw × 6w (1 w rest) 30% (37 evaluable pts)
Stemmler et al 2005 54 (all 1st line) 35 mg/m2 qw × 6w (2 w rest) 48.1%
Ford et al 2006 42 (62% 2nd line) 35mg/m2 qw × 6w (2 w rest) 26%
Weekly versus 3-week single-agent docetaxel
Sedky et al 2002 30 (overall 40% 2nd line) 35 mg/m2 qw × 6w (2w rest) 
versus 100 mg/m2 d 1 q 21
86.7% versus 73.3%
Tabernero et al 2004 41 (17% 2nd line)
42 (20% 2nd line)
40 mg/m2 qw versus 100 mg/m2 
d 1 q 21
34% versus 33%
Abbreviations: Pts, patients; ORR, complete + partial response; w, week; Anthra, anthracycline.Therapeutics and Clinical Risk Management 2008:4(5) 1052
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An ORR of 38% (14 partial responses) was found, with a TTP 
of 5 months and an OS of 12 months. Regarding toxicity, 
19% of patients experienced G3/4 neutropenia with no case 
of febrile neutropenia. Although degree of toxicity was not 
severe in many cases, it was the most common cause for delay 
of the treatment and dose reduction. None of the patients 
showed G3/4 non-hematologic toxicity. Fatigue and asthenia, 
generally mild, were observed in 35% of patients and gener-
ally mild. Gastrointestinal side effects and skin/nails changes 
were relatively frequent (38% and 39% respectively).
In 2003, Ramos et al (2003) reported on 35 MBC 
patients resistant to prior anthracycline chemotherapy 
treated with docetaxel 40 mg/m2 for 6 consecutive weeks 
followed by a 2-week rest, then reduced to 36 mg/m2 due 
to non-hematologic toxicity (28% G3/4 asthenia). ORR 
was 34% (2 CR and 10 PR). After a median follow-up of 
11.4 months, median TTP was 8.4 months, while median 
OS was 13.6 months. The most severe hematologic toxicity 
(17% of patients) was neutropenia whereas asthenia, nail, 
ocular, and skin disorders were the main non-hematologic 
toxicities. One treatment-related death occurred during 
further follow-up (pulmonary ﬁ  brosis).
In order to evaluate the safety and efﬁ  cacy of weekly 
docetaxel in frail and/or elderly patients, who were ineligible 
for the standard 3-weekly docetaxel (100 mg/m2) regimen, 
D’Hondt et al (2004) performed a phase II study for the 
treatment of 47 MBC patients. Docetaxel was given at the 
dose of 36 mg/m2 weekly for 6 weeks followed by a 1-week 
rest. There was a median of 2 prior chemotherapy regimens 
and more than 60% had a WHO performance score at base-
line of 2–3. Noteworthy, the ORR, in 37 evaluable patients, 
was 30%. Six patients experienced G3 and 4 patients G4 
neutropenia. Of these 10 patients, 4 developed neutropenic 
fever. Neurotoxicity was mild and G3 paraesthesia occurred 
in 1 patient. The authors conclude that weekly docetaxel 
(36 mg/m2) is active, safe and overall well tolerated also in 
heavily pretreated frail/elderly patients.
In a multicenter phase II study published in 2005, 
Stemmler et al (2005) prospectively analyzed the activity of 
weekly docetaxel in 54 ﬁ  rst-line MBC patients. Docetaxel 
was given at a dose of 35 mg/m2 weekly for 6 weeks fol-
lowed by 2 weeks of rest with an ORR of 48.1%. Median 
survival was 15.8 months, while median TTP was 5.9 months. 
G3 neutropenia was reported in 3.7% of patients with no 
case of febrile neutropenia. Among the non hematologic 
toxicities G3/4 asthenia was observed in 5.6% and nausea/
vomiting in 3.7% of cases. The toxicity proﬁ  le did not dif-
fer signiﬁ  cantly between younger (65 years) and elderly 
patients (65 years), except for ﬂ  uid retention syndrome 
and neurotoxicity that showed an increased incidence in the 
younger patients.
In 2006 Ford et al (2006) evaluated docetaxel 35 mg/m2 
weekly for 6 weeks followed by a 2-week rest, in 42 anthra-
cycline-pretreated MBC patients (second-line treatment in 
62% of patients). They reported an ORR of 26% (11 partial 
responses); 5 of these responding patients had relapsed 
12  months after the end of previous anthracycline-based 
chemotherapy. Myelosuppression was rare, with only 
2 patients (5%) experiencing G3 neutropenia (no G4 
neutropenia). Non-hematologic G3 toxicities were: fatigue 
17%, neuropathy 0%, hyperlacrimation 5%, stomatitis 
7%, diarrhoea 14%, and cutaneous toxicity 19% (limb/
palmar-plantar erythematous reactions, or fixed-plaque 
erythrodysaesthesia). The authors do not recommend this 
weekly regimen due to the signiﬁ  cant non-hematological 
toxicities associated with the treatment.
Sedky et al (2002) conducted a randomized phase II trial, 
presented in an abstract form, to compare weekly docetaxel 
at a dose of 35 mg/m2 for 6 weeks followed by 2 weeks 
rest, with docetaxel at a dose of 100 mg/m2 every 3 weeks 
in 30 MBC patients. There was no statistical difference 
between the weekly and the every 3-week treatment arms 
for ORR (86.7% versus 73.3% respectively), neutropenia 
being less with the weekly regimen.
A randomized phase II study (Tabernero et al 2004) 
was performed to compare weekly versus every 3-week 
docetaxel at a dose of 40 mg/m2 and 100 mg/m2, respectively, 
in 83 MBC patients. ORR was 34% in the weekly and 33% in 
the every-3-week arm; median TTP was 5.7 versus 5.3 months, 
while the median time to treatment failure was 4.1 and 
4.9 months, respectively. In terms of tolerability, the 
incidence of all G3/4 adverse events was higher in the 
every-3-week arm. In particular G3/4 neutropenia, neutrope-
nic fever, stomatitis, and neurosensory toxicity had a lower 
incidence in the weekly docetaxel arm.
Weekly docetaxel in combination 
regimens: phase II studies
Since encouraging results came from phase II studies on 
weekly single-agent docetaxel, it has been investigated in 
combination with either chemotherapeutic or biological 
agents (Table 4).
The combination of weekly docetaxel and vinorelbine 
was investigated in 57 MBC patients (ﬁ  rst line in 42 cases) 
(Kornek et al 2001). Therapy consisted of vinorelbine 
30 mg/m2 on days 1 and 15 and docetaxel 30 mg/m2 on Therapeutics and Clinical Risk Management 2008:4(5) 1053
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days 1, 8, and 15 every 28 days. Depending on the absolute 
neutrophil count on the day of scheduled administration, 
a 5-day course of G-CSF 5 μg/kg/d was given. ORR was 
64.3% in patients receiving docetaxel plus vinorelbine as 
ﬁ  rst-line chemotherapy, including 8 CR (19%) and 19 PR 
(45.3%); 11 patients (26.2%) had disease stabilization and 
4 (9.5%) experienced disease progression. As second-line 
treatment, this regimen resulted in 8 (53.3%) objective 
responses. Median TTP was 12 months in the ﬁ  rst-line and 
9.8 months in the second-line setting. After a median fol-
low-up of 18 months, 38 patients (65%) were still alive (with 
metastatic disease). Regarding hematologic side effects, G3 
or G4 neutropenia occurred in 18 patients (32%) and was 
complicated by septicemia in 4 cases; G3 or G4 thrombocy-
topenia was reported in 2 patients (4%) and G3 anemia was 
seen in 1 patient (2%). Severe (G3) non-hematologic toxici-
ties, except for alopecia, were rarely observed and included 
nausea/vomiting in 2 patients (4%) and stomatitis, peripheral 
neuropathy, and skin toxicity, each in 1 case.
A multicenter phase II study focused on weekly docetaxel 
35 mg/m2 in combination with gemcitabine 800 mg/m2 on 
days 1, 8, 15 of an every-28-days cycle as ﬁ  rst-line treatment 
in 58 MBC patients (Palmeri et al 2005). At least 1 visceral 
site of metastasis was present in 45 (77.6%) patients. In the 56 
assessable patients, ORR was 64.3% with 9 patients (16.1%) 
achieving a CR, 27 (48.2%) a PR, and 12 (21.4%) patients SD. 
Table 4 Recent selected phase II trials on weekly docetaxel in combination regimens
Author and year
of publication
N. of pts (line) Regimen ORR
Kornek et al 2001 57 (26% 2nd line) VNR 30 mg/m2 d1,15 q 4w
with Doc 30 mg/m2 d1,8,15 q 4w
64% as 1st line 53% as 2nd line
Palmeri et al 2005 58 (1st line) Doc 35 mg/ m2 d1,8,15 q 4w
with Gem 800 mg/ m2 d1,8,15 q 4w
64% (56 pts evaluable)
Mrozek et al 2006 39 Doc 30 mg/m2 qw × 3w (1 w rest) 
with Cap 800 mg/m2 bid d1-21 q 4w
44%
Esteva et al 2002 30 (19% 2nd line) Doc 35 mg/m2 qw × 3w (1 w rest) 
with T 2 mg/kg qw × 3w (1w rest)
63%
Raab et al 2002 13 (1st line) 12 Doc 35 mg/m2 qw × 6w (2 w rest) + 
T 2 mg/kg/qw versus Doc 100 mg/m2 
d1 q21 + T 2 mg/kg/qw
Overall 63%
Tedesco et al 2004 26 (15% 2nd line) Doc 35 mg/m2 qw × 6w
with T 2 mg/kg qw × 3w
50%
Raaf et al 2004 21 + 14 Doc 33 mg/m2 d1,8,15 q 4w
Doc 40 mg/m2 d1,8,15 q 4w +
T 2 mg/kg d8,15 q 4w
21%
+ 17 (Her2 +) 59%
(T only for 17 additional Her2 + pts)
Ramaswamy et al 2006 27 (22% 2nd line) Doc 35 mg/m2 d1,8,15 q 4w with
B 10 mg/kg d1,15 q 4w
52%
Ghosn et al 2008 63 (1st line) NAVCAP 8 cycles versus NAVCAP
4 cycles + Doc qw x 12 wk
 (Overall 65% after ﬁ  rst
4 cycle of NAVCAP) Not yet 
available
Peacock et al 2008 61 (1st line) Doc 30 mg/m2 d1,8 q 3w with VNR 
25/mg/m2 d1,8 q3w
with T 2 mg/kg qw
67%
Rosati et al 2008 20 + 28
(All 1st line)
Doc 30 mg/m2 qw × 3w (1 w rest)
or P 50 mg /m2 qw × 3w (1 w rest)
with NPL-Anthra 25 mg /m2 qw x 3w 
(1 w rest) 
Overall 73%
Waterhouse et al 2008 33 (55% 1st line) Doc 30 mg /m2 qw × 3w (1w rest) 
with Imatinib 600 mg daily
20% (18 evaluable pts)
Abbreviations: Pts, patients; ORR, complete + partial response; w, week; VNR, vinorelbine; Doc, docetaxel; G, gemcitabine; Cap, capecitabine; T, trastuzumab; P, paclitaxel; 
B, bevacizumab; NAVCAP,   VNR 25 mg/m2 d1, 8 + Cap 825 mg/m2 bid D1–14 q3w; NPL-Anthra, non-pegylated liposomal anthracycline.Therapeutics and Clinical Risk Management 2008:4(5) 1054
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Median survival was 22.10 months, with 43 (74.1%) patients 
still alive at the cut-off date of 36 months. Noteworthy, TTP 
was 13.6 months. Median time to treatment failure was 8.6 
months (95% CI: 4.79–12.41). At the time of cut off, 24 patients 
had experienced progressive disease (PD). Median duration of 
response in patients with SD was 19.27 months. Furthermore, 
median survival of patients who achieved PR was 29.30 months. 
G3/4 neutropenia occurred in 8 patients (14%). Regarding non-
hematologic toxicity, G3 alopecia was experienced by 5 patients 
(9%). No case of ﬂ  uid retention syndrome was seen.
The activity and tolerability of weekly docetaxel 
(30 mg/m2 on days 1, 8, and 15) and capecitabine (800 mg/m2 
twice daily on days 1–21) repeated every 28 days was 
evaluated in 39 patients with MBC (Mrozek et al 2006). ORR 
was 44%, with a median duration of response of 9.1 months. 
Median TTP was 5.5 months. G3 non-hematologic toxicities 
were asthenia (18%), diarrhea (18%), nausea/vomiting (13%), 
stomatitis (13%), and hand-foot syndrome (10%); among the 
hematological toxicities, 13% of patients experienced neu-
tropenia. There were 2 G4 toxicities (febrile neutropenia and 
pulmonary embolism).
In HER-2 overexpressing MBC patients, weekly 
docetaxel has been largely evaluated in combination with 
trastuzumab.
A phase II study was performed in 30 MBC women 
(19% in second line) with a median age of 45 years (Esteva 
et al 2002). The authors evaluated docetaxel 35 mg/m2/
week and trastuzumab (loading dose of 4 mg/kg followed 
by 2 mg/kg) weekly for 3 weeks followed by 1-week rest. 
They reported an ORR of 63% (RP in 19 patients); according 
to the HER-2 extracellular domain level, 21 patients with 
baseline levels 14.9 ng/ml had an ORR of 76% while those 
with normal levels had an ORR of 33%. The median TTP was 
9 months. The main G3/4 toxicities were granulocytopenia 
(26%), fatigue (20%), and diarrhea (6%).
A phase II randomized study compared every-3-week 
docetaxel and trastuzumab with a weekly regimen (docetaxel 
35 mg/m2 for 6 weeks with 2-week rest) as first-line 
treatment in 25 patients with anthracycline-pretreated, 
HER-2 overexpressing MBC (Raab et al 2002). Overall 
the ORR was 63% and median TTP was 8.3 months. G3/4 
hematologic side effects were frequent in the every-3-week 
group, including leukopenia, neutropenia (92%), and febrile 
neutropenia (23%).
A phase II study evaluated the combination of weekly 
docetaxel (35 mg/m2/week for 6 weeks) and trastuzumab 
(4 mg/kg load; 2 mg/kg/week) as first- or second-line 
(15%) therapy in 26 women with HER-2-overexpressing 
MBC (Tedesco et al 2004). ORR was 50%. With regard to 
HER-2 3+ patients, the reported ORR was 63%, compared 
with a 14% response rate for HER-2 2+ patients (p = 0.07). 
Patients with FISH-positive tumors experienced an ORR 
of 64%. Median time to progression was 12.4 months for 
the entire group and median survival was 22.1 months. G4 
toxicities occurred in 4 patients.
The combination of weekly docetaxel and trastuzumab 
was also evaluated in 52 MBC patients (Raff et al 2004). 
They received docetaxel given on 2 different sched-
ules: 21 patients in group 1A, 33 mg/m2 weekly; 14 in group 
1B, 40 mg/m2 weekly for 3 weeks with 1-week rest. Patients 
with HER-2/neu overexpressing disease also received 
trastuzumab 4 mg/kg on day 1, then 2 mg/kg on days 8 and 
15 of each 28-day cycle (group 2). Previous every-3-week 
taxane therapy had been used for metastatic disease in 19 of 
35 patients (54%) in group 1A/B and in 2 of 17 patients 
(12%) in group 2. ORR (PR) was 21% in patients treated 
with docetaxel alone, including 3 of 19 taxane-pretreated 
patients (16%) and 4 of 16 taxane-naive patients (25%). 
Partial response occurred in 59% of cases treated with 
docetaxel/trastuzumab. Median TTP was 4.5 months in the 
docetaxel group and 8.5 months in the docetaxel/trastuzumab 
group. The main G3/4 toxicities (10% of patients) observed 
were neutropenia (21%), pulmonary toxicity (12%), and 
hyperglycemia (10%).
Finally, a pilot study of preoperative weekly trastuzumab 
(4 mg/kg loading dose, then 2 mg/kg/week), in association 
with weekly epidoxorubicin 30 mg/m2/week and docetaxel 
35 mg/m2/week for 6 weeks with 1 week was conducted on 
14 consecutive patients (Wenzel et al 2004). Overall the 
regimen was well tolerated, with major responses observed 
in 12 out of 14 patients (86%) leading to breast-conserving 
surgery in 11 of 14 patients (79%).
The safety and efﬁ  cacy of bevacizumab and weekly 
docetaxel as ﬁ  rst or second line treatment was evaluated in 
27 MBC patients (Ramaswamy et al 2006). ORR was 52% 
and the median progression-free survival was 7.5 months. 
The most common G4 toxicities were: pulmonary embolus 
(7%), febrile neutropenia (4%), and infection (4%).
Four recent studies evaluating weekly docetaxel in combi-
nation with both chemotherapeutic and/or biological agents, 
for the treatment of MBC were presented at the 2008 ASCO 
annual meeting, demonstrating the growing interest for such 
a feasible and active schedule.
On the basis of a proven prolonged TTP and OS 
of the sequential use of vinorelbine (25 mg/m2 d1,8) 
and capecitabine (825 mg/m2 bid d1–14) (NAVCAP) Therapeutics and Clinical Risk Management 2008:4(5) 1055
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every 3 weeks for 4 cycles followed by 12 consecutive 
weeks of docetaxel (25 mg/m2/w) in the ﬁ  rst-line treatment 
of MBC, Ghosn et al (2008b) designed and conducted a 
further phase II randomized trial. Preliminary data from 
this study have been also presented in abstract form (Ghosn 
et al 2008a). Sixty-three ﬁ  rst-line HER-2/neu negative MBC 
patients were enrolled and 44 have been randomized after the 
ﬁ  rst 4 cycles of NAVCAP to receive either 4 more cycles of 
NAVCAP (25 patients) or 12 weekly docetaxel (19 patients). 
Overall, after the ﬁ  rst 4 cycles of NAVCAP an ORR of 
65% with 17% of CR was registered (SD 21%). Nineteen 
and 12 patients had completed the treatment plan at the time 
writing. With regard to tolerability, patients treated with 
NAVCAP experienced G3 neutropenia in 8% of cases, G3/4 
anemia in 6%, and 1 patient had G3 hand-foot syndrome; in 
patients treated with docetaxel, 11% had G4 liver enzymes 
elevation and 1 patient had G4 creatinine elevation. No long-
term follow-up data were available in order to determine 
whether maintenance docetaxel will have an added value 
versus maintenance NAVCAP.
The feasibility and safety of a 3-drug combination of 
trastuzumab, docetaxel, and vinorelbine as ﬁ  rst-line therapy 
was investigated in 61 HER-2 positive MBC. The schedule 
included docetaxel 30 mg/m2 and vinorelbine 25 mg/m2 on 
days 1 and 8 of a 3-week cycle in association with weekly 
trastuzumab (4 mg/kg loading dose followed by 2 mg/kg/
week) (Peacock et al 2008). The reported ORR was 67% 
(CR 26%, PR 41%). After a median follow-up of 58 months, 
median progression-free survival was 11.3 months and 
median OS was 39.1 months. The most common hematologic 
toxicity was neutropenia (G4 in 72%); 8 patients (13%) were 
hospitalized for febrile neutropenia. Other G3/4 toxicities 
included fatigue (12%), hyperglycemia (7%), and myalgias 
(7%).
Rosati et al (2008) presented results of their phase I/II 
trial in ﬁ  rst-line MBC patients (adjuvant anthracyclines and 
taxanes were allowed). The dose-ﬁ  nding study examined 
the safety and activity of weekly combination (d 1, 8, 15 
q4w) of paclitaxel (n = 28 patients) or docetaxel (n = 20 
patients) with non-pegylated liposomal anthracycline. DLT 
was 50 mg/m2 and 30 mg/m2 for paclitaxel and docetaxel 
respectively, combined with 25 mg/m2 of non-pegylated lipo-
somal anthracycline. A phase II trial followed and 48 patients 
were enrolled. The reported ORR was 73% (12.5% CR and 
60.41% PR), with a clinical beneﬁ  t of 85.41%. Median TTP 
was 10.68 months. No survival differences were recorded 
between paclitaxel and docetaxel groups. G3/4 toxicities 
included neutropenia (68.75%) and alopecia (60.41%). 
Overall the following non-hematologic toxicities were 
signiﬁ  cantly higher for docetaxel than paclitaxel: mucositis 
12.53% versus 8.3%, onycholysis 22.91% versus 10.41%, 
and peripheral sensory neuropathy 25% versus 14.58%. The 
authors concluded that weekly administration of taxane and 
non-pegylated liposomal anthracycline is well tolerated and 
clinical beneﬁ  t data encourage a phase III study design.
The association between weekly docetaxel and imatinib 
mesilate has been studied in a phase II study designed 
to investigate whether adding imatinib could ameliorate 
docetaxel performance in ﬁ  rst- or second-line MBC patients 
(Waterhouse et al 2008).
Docetaxel was given weekly 30 mg/m2 days 1, 8, and 15 
q28 for 6 cycles with daily oral imatinib 600 mg until PD. To 
date, only data on toxicity of 33 patients have been published 
(55% ﬁ  rst line and 42% second line; 13 patients had prior 
taxanes). Overall, hematologic side effects were mild with 
G3/4 neutropenia 12% (1 febrile neutropenia) and anemia 
9%. On the other hand, G3/4 non-hematologic, especially 
gastrointestinal, toxicity prompted imatinib dose modiﬁ  ca-
tion to 400 mg after the ﬁ  rst 14 patients. No improvement 
in gastrointestinal toxicity has been recorded despite dose 
reduction: G3/4 diarrhea 21%, nausea 18%, and vomiting 
12%, with 9 patients requiring treatment–related hospitaliza-
tions (gastrointestinal toxicity 4, febrile neutropenia 1, pleural 
effusion 2, and pneumonia 2). Only 5 patients went on to 
maintenance imatinib with a median of 6 cycles. Four out of 
18 evaluable patients had PR, 8 patients SD, while 6 patients 
progressed. Median TTP and OS were 3 and 10 months, 
respectively. Although presented data are preliminary, no 
therapeutic advantage resulted from adding imatinib to 
weekly docetaxel in MBC.
Weekly single-agent docetaxel: 
phase III studies
To date only 3 phase III randomized trials have been 
performed to investigate the efﬁ  cacy of weekly docetaxel 
(Table 5).
In 2004, Meier et al reported, in abstract form, a planned 
interim analysis of a phase III trial comparing weekly 
vinorelbine versus weekly docetaxel for metastatic breast can-
cer failing anthracyclines (Meier et al 2004). Crossing-over 
was allowed on disease progression. They analyzed data from 
120 of 240 patients accrued from November 1998 until July 
2003 and randomized to receive either vinorelbine 30 mg/m2 
or docetaxel 35 mg/m2 weekly for 6 consecutive weeks of a 
8-week cycle. At the time of the analysis 112 patients were 
evaluable. TTP was the main endpoint of the study: 81 days Therapeutics and Clinical Risk Management 2008:4(5) 1056
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(CI: 67–99) versus 103 days (CI: 98–119) were registered 
for vinorelbine versus docetaxel (p = 0.1178). OS was 253 
(CI: 173–331) versus 288 days (CI: 231–424) for initial 
vinorelbine versus docetaxel (p = 0.1895). Signiﬁ  cantly 
more patients receiving vinorelbine (42%) had disease pro-
gression as best response than patients receiving docetaxel 
(18%) (p = 0.00751). Moreover, vinorelbine resulted in more 
treatment delays (76% versus 46%), more leukopenia (61% 
versus 10%) and G3/4 neutropenia (43% versus 7%), but 
less mucositis/stomatitis (1% versus 8%) (all p  0.05). The 
authors found weekly docetaxel more efﬁ  cient at response 
and less toxic than weekly vinorelbine, but more mature data 
are needed in order to clarify the beneﬁ  t. To our knowledge, 
no deﬁ  nitive data are available to date.
Burstein et al studied the combination of trastuzumab 
with either vinorelbine or a taxane as ﬁ  rst-line treatment 
in 81 out of the 250 originally planned HER-2 positive 
MBC patients (the study was terminated early because of 
poor accrual) (Burstein et al 2007). The primary endpoint 
was ORR. Patients were randomized 1:1 to receive either 
trastuzumab 4 mg/kg loading dose and then 2 mg/kg/week 
with weekly vinorelbine (25 mg/m2 q week for 8 weeks) or 
weekly taxanes (paclitaxel 80 mg/m2 q week for 8 weeks or 
docetaxel 35 mg/m2 q week for 8 weeks at the investigator’s 
choice). Forty-one patients and 40 patients were randomized 
to the vinorelbine/trastuzumab and the taxane/trastuzumab 
arm, respectively (docetaxel n = 24; paclitaxel n = 14, 
with 2 more patients receiving paclitaxel and carboplatin). 
Overall, ORR was 51% in the vinorelbine/trastuzumab 
arm and 40% in the taxane/trastuzumab arm (p = 0.37). 
Median TTP was not significantly different between 
the vinorelbine- and taxane-based arms (8.5 versus 6.0 months, 
p = 0.09). Noteworthy chemotherapy administration delays 
were more frequent in the vinorelbine containing arm (82% 
of patients experienced at least 1 week of delay) than the 
taxane-based arm (overall 60%, 56% for paclitaxel and 
63% for docetaxel). With regard to tolerability, anemia and 
neutropenia were more common with vinorelbine treatment. 
Alopecia, rash, and nail changes were reported to be more 
frequently associated with taxane-containing therapy. Among 
patients treated with docetaxel, 2 had ﬂ  uid retention syndrome 
and 5 hyperlacrimation. In the vinorelbine arm, 2 patients 
went off study for cardiac toxicity. The authors concluded 
that either weekly vinorelbine/trastuzumab or weekly taxane/
trastuzumab are active and feasible and can be considered 
for the ﬁ  rst-line treatment of HER-2 overexpressing MBC 
patients, even if some caution is required when interpreting 
these results due to the small proportion of patients included 
leading to the early termination of the study.
A recent phase III trial was conducted randomizing 118 
MBC patients to receive docetaxel on an every-3-week 
versus weekly basis (Rivera et al 2008). Fifty-nine patients 
received docetaxel 75 mg/m2 every 3 weeks and 59 docetaxel 
35 mg/m2 for 3 consecutive weeks with 1 week of rest. ORR 
was 35.6% for the 3-week versus 20.3% for the weekly 
schedule. No statistically signiﬁ  cant difference was observed 
both in terms of progression-free survival (5.7 months versus 
5.5, p = 0.46) and OS (18.3 versus 18.6 months, p = 0.34). 
A signiﬁ  cantly higher toxicity rate, G3/4, was found in the 
every-3-week treatment arm versus the weekly treatment arm 
(88.1% versus 55.9%, respectively; p = 0.0001). The trial was 
terminated early after an interim analysis performed in June 
2005 because of a slow accrual rate.
Due to the early termination this study was signiﬁ  cantly 
underpowered even in the authors’ opinion, so that it remains 
unknown whether a larger phase III study could demonstrate 
Table 5 Phase III trials
Author and year
of publication
N. of pts Regimen TTP (months) PFS OS
Meier et al 2004 55 Doc 35 mg/m2 qw × 6w (2w rest) 
versus VNR 30 mg/m2 qw × 6w 
(2w rest)
2.7 versus 3.4 Not reported 9.6 months versus 
8.43 months
57 (p = 0.1178)  (p = 0.1895)
Burstein et al 2007 40 Doc 35 mg/m2 × 8w/P 80 mg/m2 × 
8w + T 2mg/kg qw versus
VNR mg/m2 + T 2 mg/kg qw
6 versus 8.5
  Not reported Not reported
41  (p = 0.09)
Rivera et al 2008 59 Doc 75 mg/m2 d 1 q 21 versus
Doc 35 mg/m2 d 1,8,15 q 28
Not reported 5.7 months versus 18.3 months versus
59 5.5 18.6
(p = 0.46) (p = 0.34).
Abbreviations: Pts, patients; BC, breast cancer; TTP,  time to progression; OS, overall survival; w, week; Doc, docetaxel; VNR, vinorelbine.Therapeutics and Clinical Risk Management 2008:4(5) 1057
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differences in OS and/or progression-free survival. Neverthe-
less, modest increases in response rate are unlikely to affect 
OS in patients with advanced MBC.
Conclusion
Since the main goal of MBC management remains palliation, 
maximizing the antitumor activity and maintaining a favorable 
toxicity proﬁ  le appears of paramount relevance in this setting. 
To date, combinations containing the taxanes represent the 
standard of care for ﬁ  rst-line treatment of these patients. Both 
docetaxel and paclitaxel can be administered weekly, achiev-
ing comparable efﬁ  cacy results with lower toxicity compared 
with standard schedules (Zimatore et al 2002).
Particularly, several docetaxel-containing schedules and 
associations have been tested: overall, weekly, rather than 
the standard every-3-week dosing can provide good efﬁ  cacy 
results and better tolerability, even in heavily pretreated 
patients with refractory disease and/or in elderly/poor PS 
women. Unfortunately because there is a great difference 
between the various experimented weekly schedules (ie, 
d1,8 q21 or d1,8,15 q28 or 6 consecutive weeks) and the 
doses employed are vary greatly as well (range from 25 to 
40 mg/m2), it is not possible to draw any deﬁ  nitive conclusion 
on which is the best dose and timing of administration.
Reviewing the main phase II studies results, it has been 
highlighted that the obtained ORR can vary between 26% and 
86% or 20% and 73% with docetaxel as a single agent or in 
combination, respectively, depending on doses, associations, 
and line of treatment.
Furthermore, the lower incidence of severe hematologic 
toxicities and acute non-hematologic side-effects allows its 
use in most MBC patients both as single-agent and as part 
of combination regimens.
The association with biological agents (trastuzumab, 
bevacizumab) represents a promising therapeutic option 
given the favorable toxicity proﬁ  le of these drugs.
Overall, published data support the administration of 
weekly docetaxel for the treatment of MBC patients even 
with the lack of data from phase III randomized trials, and 
keeping in mind the drawbacks of weekly regimens (eg, more 
frequent hospital visits).
The choice of the best docetaxel weekly schedule in 
patients with MBC should be based on patient characteristics 
and on the risk of developing toxic effects. In elderly or unﬁ  t 
patients weekly docetaxel could be preferred.
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